Update on inotropic therapy in the management of acute heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 9, Issue 6, 2007, Pages 443-449

  Landmesser, Ulf ^a   Drexler, Helmut ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM SENSITIZER; CAPTOPRIL; CARDIOTONIC AGENT; CARVEDILOL; CHLORTALIDONE; CYCLIC AMP; DIGITALIS; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; HEPARIN; HYDROCHLOROTHIAZIDE; INOTROPIC AGENT; ISOSORBIDE DINITRATE; ISTAROXIME; LEVOSIMENDAN; LIDOCAINE; MILRINONE; NORADRENALIN; OXYGEN; PLACEBO; SPIRONOLACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE AGENT; VASODILATOR AGENT;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; CELL DEATH; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; FORWARD HEART FAILURE; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; LONG TERM CARE; MORTALITY; OPTIMAL DRUG DOSE; PATIENT SELECTION; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA;

EID: 36749074589     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-007-0039-9     Document Type: Review

References (32)

1. Gheorghiade M, Zannad F, Sopko G, et al.: Acute heart failure syndromes: current state and framework for future research. Circulation 2005, 112:3958-3968.
2. Nieminen MS, Bohm M, Cowie MR, et al.: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26:384-416.
3. Gheorghiade M, Zannad F: Modern management of acute heart failure syndromes. Eur Heart J Suppl 2005, 7(suppl B):B3-B7.
4. Nieminen MS, Brutsaert D, Dickstein K, et al.: EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006, 27:2725-2736.
5. Packer M: The search for the ideal positive inotropic agent. N Engl J Med 1993, 329:201-202.
6. Stevenson LW: Inotropic therapy for heart failure. N Engl J Med 1998, 339:1848-1850.
7. O'Connor CM, Gattis WA, Uretsky BF, et al.: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999, 138(1 Pt 1):78-86.
8. Cuffe MS, Califf RM, Adams KF Jr, et al.: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547.
9. Thackray S, Easthaugh J, Freemantle N, and Cleland JG: The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta-regression analysis. Eur J Heart Fail 2002, 4:515-529.
10. Zairis M: The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: CASINO study [abstract]. J Am Coll Cardiol 2004, 43:206A.
11. Packer M, Carver JR, Rodeheffer RJ, et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991, 325:1468-1475.
12. Landmesser U, Drexler H: Chronic heart failure: an overview of conventional treatment versus novel approaches. Nat Clin Pract Cardiovasc Med 2005, 2:628-638.
13. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial [no authors listed]. Lancet 1999, 353:9-13.
14. Packer M, Fowler MB, Roecker EB, et al.: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106:2194-2199.
15. De Luca L, Colucci WS, Nieminen MS, et al.: Evidence-based use of levosimendan in different clinical settings. Eur Heart J 2006, 27:1908-1920.
16. Kass DA, Solaro RJ: Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006, 113:305-315.
17. Papp Z, Csapo K, Pollesello P, et al.: Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 2005, 23:71-98.
18. Michaels AD, McKeown B, Kostal M, et al.: Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005, 111:1504-1509.
19. Follath F, Cleland JG, Just H, et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002, 360:196-202.
20. Moiseyev VS, Poder P, Andrejevs N, et al.: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002, 23:1422-1432.
21. Mebazaa A, Nieminen MS, Packer M, et al.: Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007, 297:1883-1891.
22. Packer M, REVIVE-II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Paper presented at the American Heart Association Scientific Sessions. Dallas, TX; November 13-16, 2005.
23. Aaronson KD, Eppinger MJ, Dyke DB, et al.: Left ventricular assist device therapy improves utilization of donor hearts. J Am Coll Cardiol 2002, 39:1247-1254.
24. Yan C, Miller CL, Abe J: Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 2007, 100:489-501.
25. Metra M, Nodari S, D'Aloia A, et al.: Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002, 40:1248-1258.
26. Felker GM, Benza RL, Chandler AB, et al.: Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003, 41:997-1003.
27. Hasenfuss G, Pieske B, Castell M, et al.: Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998, 98:2141-2147.
28. Brixius K, Reicke S, Schwinger RH: Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol 2002, 282:H131-H137.
29. Givertz MM, Andreou C, Conrad CH, Colucci WS: Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships. Circulation 2007, 115:1218-1224.
30. Kivikko M, Lehtonen L, Colucci WS: Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003, 107:81-86.
31. Ghali JK, Smith WB, Torre-Amione G, et al.: A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Am J Cardiol 2007, 99:47A-56A.
32. Shin DD, Brandimarte F, De Luca L, et al.: Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007, 99(2A):4A-23A.